Evidence map›Paper›PMID 41422223›Full record

ArticleJournal of nanobiotechnology2025

Manganese-enriched nanoboron agent amplifies BNCT efficacy via pyroptosis-mediated immune activation and STING pathway synergy​.

Zhicheng Zhang, Xiaoyan Sun, Yaxin Qin, Yufan Yang, Qi Dai, Xiaoyan Bao, Minoru Suzuki, Sheng Wang, Zai Yang, Zhifeng Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhicheng ZhangDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310058, China.
Xiaoyan SunCollege of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Yaxin QinCollege of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Yufan YangCollege of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Qi DaiDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310058, China.
Xiaoyan BaoCollege of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, 310058, China.
Minoru SuzukiDivision of Particle Radiation Oncology, Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2- 1010, Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan.
Sheng WangDepartment of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, No. 28, Xianning West Road, Xi'an, 710049, Shaanxi, China.
Zai YangDepartment of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, No. 28, Xianning West Road, Xi'an, 710049, Shaanxi, China.
Zhifeng LiDepartment of Nuclear Science and Technology, School of Energy and Power Engineering, Xi'an Jiaotong University, No. 28, Xianning West Road, Xi'an, 710049, Shaanxi, China.
Min HanDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310058, China. hanmin@zju.edu.cn.
Donghang XuDepartment of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China. xudonghang@zju.edu.cn.
Qichun WeiDepartment of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310058, China. qichun_wei@zju.edu.cn.

Funding

National Key Research and Development Program of China 2022YFE0107800National Key Research and Development Program of China 2023YFA1008600National Key Research and Development Program of China 2024YFA1613800National Natural Science Foundation of China 82373206
6 · The paper itself

Abstract

Boron Neutron Capture Therapy (BNCT) offers selective tumor cell ablation with minimal damage to normal tissues, but its efficacy is limited by therapy-induced immunosuppression and high intratumoral H

Indexed as

Boron Neutron Capture TherapyManganeseMembrane ProteinsPyroptosisAnimalsBoronCD8-Positive T-LymphocytesCell Line, TumorDendritic CellsFemaleHumansManganese CompoundsMiceMice, Inbred C57BLSerum Albumin, BovineSignal TransductionBoronManganeseManganese CompoundsMembrane ProteinsSerum Albumin, Bovine

Identifiers

PMID41422223
PMCPMC12837054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.